Can Amgen's Drug Improve Sjogren's Disease Treatment?

Sjogren's disease treatment could see a significant development after Amgen reported positive Phase 3 results for its experimental drug dazodalibep.

The OASIZ-301 study found that both tested dosing regimens significantly reduced systemic disease activity over 48 weeks compared with placebo.

The findings are important for an autoimmune disorder that currently has no US FDA-approved disease-modifying therapies targeting its underlying causes.

Amgen's results also highlight the potential of CD40L-targeted therapies to address symptoms beyond dryness, including systemic inflammation.

The company is continuing its broader clinical program to evaluate the drug's therapeutic potential.

Key Highlights

• Amgen's OASIZ-301 Phase 3 trial enrolled 648 patients with Sjogren's disease.
• Both dazodalibep regimens met the primary endpoint at Week 48.
• The four-week dosing regimen also significantly improved patient-reported dryness.
• Amgen is conducting additional Phase 3 research to assess the drug in another patient population.

Also Read: AI in Pharma Quality: Opportunities and Compliance Challenges

How Did Amgen's Dazodalibep Perform in Phase 3?

The 1,500 mg regimen, administered every four weeks, reduced ESSDAI disease activity scores by 5.6 points, compared with 3.8 points for placebo. The 3,000 mg regimen, administered every 12 weeks, achieved a 5.2-point reduction.

The treatment effect was observed as early as Week 4 and continued through Week 48. The four-week regimen also improved patient-reported dryness, with statistically significant differences against the placebo.

Ghaith Noaiseh, associate professor of medicine at the University of Kansas Medical Center and lead investigator, said the disease's complexity includes dryness, fatigue, joint pain and systemic manifestations affecting organs such as the lungs, kidneys and nervous system.

Why Does Sjogren's Disease Treatment Need New Approaches?

Sjogren's is an autoimmune condition in which immune activity affects moisture-producing glands and can involve multiple organs.

Existing management largely focuses on relieving dry eyes and mouth, while systemic manifestations may require immunomodulatory medicines.

Dazodalibep targets CD40L-mediated immune signaling. Its mechanism is designed to disrupt interactions involving T cells, B cells and other antigen-presenting cells, potentially addressing underlying immune activity rather than dryness alone.

What Comes Next for Amgen's Sjogren's Disease Treatment?

Amgen is conducting OASIZ-303, another Phase 3 study involving patients with high symptom burden but low systemic disease activity, to help establish whether dazodalibep benefits a broader range of patients.

Further Phase 3 evidence will determine whether this experimental Sjogren's disease treatment can progress towards regulatory approval.

The November results strengthen the clinical case for dazodalibep, but regulatory approval and further evidence remain necessary before it can become an established treatment option.